Stephan D. Thomé

1.6k total citations · 1 hit paper
21 papers, 1.1k citations indexed

About

Stephan D. Thomé is a scholar working on Oncology, Hematology and Genetics. According to data from OpenAlex, Stephan D. Thomé has authored 21 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Hematology and 5 papers in Genetics. Recurrent topics in Stephan D. Thomé's work include Multiple Myeloma Research and Treatments (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Chronic Myeloid Leukemia Treatments (3 papers). Stephan D. Thomé is often cited by papers focused on Multiple Myeloma Research and Treatments (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Chronic Myeloid Leukemia Treatments (3 papers). Stephan D. Thomé collaborates with scholars based in United States, Canada and Germany. Stephan D. Thomé's co-authors include Charles L. Loprinzi, Michael P. Heldebrant, Daniel J. Sargent, Sharlene Gill, S. Stephen, Daniel G. Haller, Guido Francini, Richard M. Goldberg, Lois E. Shepherd and Wei Chen and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Stephan D. Thomé

19 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?

2004 756 citations Sharlene Gill, Charles L. Loprinzi et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stephan D. Thomé United States	9	829	365	204	182	177	21	1.1k
L. Leong United States	16	648 0.8×	144 0.4×	238 1.2×	199 1.1×	241 1.4×	41	1.0k
Virginie Lucas United States	13	779 0.9×	429 1.2×	103 0.5×	130 0.7×	235 1.3×	24	1.1k
J. Feng China	15	660 0.8×	175 0.5×	221 1.1×	291 1.6×	425 2.4×	71	1.0k
H.‐G. Mergenthaler Germany	12	543 0.7×	206 0.6×	105 0.5×	111 0.6×	212 1.2×	33	903
Sandra J. Casak United States	18	455 0.5×	148 0.4×	189 0.9×	171 0.9×	215 1.2×	32	1.0k
Briant Fruth United States	10	547 0.7×	175 0.5×	152 0.7×	169 0.9×	281 1.6×	28	781
Luis Chu United States	12	797 1.0×	309 0.8×	225 1.1×	399 2.2×	539 3.0×	18	1.5k
Pei-Rong Ding China	20	1.2k 1.4×	145 0.4×	532 2.6×	195 1.1×	271 1.5×	45	1.6k
Lucio Giustini Italy	20	884 1.1×	294 0.8×	322 1.6×	385 2.1×	407 2.3×	41	1.3k
L. Kayitalire France	17	745 0.9×	123 0.3×	173 0.8×	163 0.9×	453 2.6×	40	1.1k

Countries citing papers authored by Stephan D. Thomé

Since Specialization

Citations

This map shows the geographic impact of Stephan D. Thomé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephan D. Thomé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephan D. Thomé more than expected).

Fields of papers citing papers by Stephan D. Thomé

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephan D. Thomé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephan D. Thomé. The network helps show where Stephan D. Thomé may publish in the future.

Co-authorship network of co-authors of Stephan D. Thomé

This figure shows the co-authorship network connecting the top 25 collaborators of Stephan D. Thomé. A scholar is included among the top collaborators of Stephan D. Thomé based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephan D. Thomé. Stephan D. Thomé is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Fuentes, Harry E, et al.. (2025). CDX2 expression as a predictive and prognostic biomarker of 5-FU response in cancer of unknown primary. ESMO Open. 10(8). 105515–105515.

2.

Cathcart-Rake, Elizabeth, David Zahrieh, Susan E. Young, et al.. (2023). A five arm natural history study of nasal vestibulitis. Cancer Medicine. 12(8). 9650–9654. 1 indexed citations

3.

Cathcart-Rake, Elizabeth, David Zahrieh, Susan E. Young, et al.. (2021). Natural history of nasal vestibulitis associated with paclitaxel, docetaxel, and other chemotherapy agents: a Minnesota Cancer Clinical Trials Network (MNCCTN) study. Supportive Care in Cancer. 29(11). 6253–6258. 1 indexed citations

4.

Leung, Nelson, Stephan D. Thomé, & Angela Dispenzieri. (2018). Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone. Haematologica. 103(3). e135–e137. 42 indexed citations

5.

Lynch, Henry T., Carrie Snyder, Jane F. Lynch, & Stephan D. Thomé. (2011). Familial Plasma Cell Disorders and Associated Cancers. Clinical Lymphoma Myeloma & Leukemia. 11(1). 80–81.

6.

Graß, Sandra, Stephan D. Thomé, Dennis D. Weisenburger, et al.. (2011). Paraproteins of familial MGUS/multiple myeloma target family-typical antigens: hyperphosphorylation of autoantigens is a consistent finding in familial and sporadic MGUS/MM. Blood. 118(3). 635–637. 22 indexed citations

7.

Bardia, Aditya, Charles L. Loprinzi, Axel Grothey, et al.. (2010). Adjuvant Chemotherapy for Resected Stage II and III Colon Cancer: Comparison of Two Widely Used Prognostic Calculators. Seminars in Oncology. 37(1). 39–46. 23 indexed citations

8.

Coleman, Elizabeth Ann, Henry T. Lynch, Carol Enderlin, et al.. (2009). Initial Report of a Family Registry of Multiple Myeloma. Cancer Nursing. 32(6). 456–464. 5 indexed citations

9.

Lynch, Henry T., et al.. (2008). Genetic counseling for DAPK1 mutation in a chronic lymphocytic leukemia family. Cancer Genetics and Cytogenetics. 186(2). 95–102. 1 indexed citations

10.

Lynch, Henry T., Bart Barlogie, Elizabeth Ann Coleman, et al.. (2008). Familial Myeloma. New England Journal of Medicine. 359(2). 152–157. 58 indexed citations

11.

Thomé, Stephan D., et al.. (2007). Translational correlates, including outcome for patients with ER-/PR-/HER2- (triple negative (TNeg)) disease from N0234, a phase II trial of gemcitabine and erlotinib for pts with previously treated metastatic breast cancer (MBC). Journal of Clinical Oncology. 25(18_suppl). 1071–1071. 3 indexed citations

12.

Lynch, Henry T., et al.. (2006). Family information service (FIS) in a BRCA1 extended family. Journal of Clinical Oncology. 24(18_suppl). 1028–1028. 3 indexed citations

13.

Gill, Sharlene, Charles L. Loprinzi, Daniel J. Sargent, et al.. (2004). Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?. Journal of Clinical Oncology. 22(10). 1797–1806. 756 indexed citations breakdown →

14.

Hogan, Marie C., Augustine Lee, Lawrence A. Solberg, & Stephan D. Thomé. (2002). Unusual presentation of multiple myeloma with unilateral visual loss and numb chin syndrome in a young adult. American Journal of Hematology. 70(1). 55–59. 39 indexed citations

15.

Menke, David M., Ethel Cesarman, Eric Green, et al.. (2002). Analysis of the Human Herpesvirus 8 (HHV-8) Genome and HHV-8 vIL-6 Expression in Archival Cases of Castleman Disease at Low Risk for HIV Infection. American Journal of Clinical Pathology. 117(2). 268–275. 37 indexed citations

16.

Thomé, Stephan D., Charles L. Loprinzi, & Michael P. Heldebrant. (2002). Determination of Potential Adjuvant Systemic Therapy Benefits for Patients With Resected Cutaneous Melanomas. Mayo Clinic Proceedings. 77(9). 913–917. 8 indexed citations

17.

Rao, Ravi D., Stephan D. Thomé, Judith R. OʼFallon, et al.. (2002). Safety of thrice-daily hyperfractionated radiation and BCNU for high-grade gliomas. International Journal of Radiation Oncology*Biology*Physics. 53(2). 376–384. 8 indexed citations

18.

Thomé, Stephan D., Charles L. Loprinzi, & Michael P. Heldebrant. (2002). Determination of Potential Adjuvant Systemic Therapy Benefits for Patients With Resected Cutaneous Melanomas. Mayo Clinic Proceedings. 77(9). 913–917. 4 indexed citations

19.

Loprinzi, Charles L. & Stephan D. Thomé. (2001). Understanding the Utility of Adjuvant Systemic Therapy for Primary Breast Cancer. Journal of Clinical Oncology. 19(4). 972–979. 63 indexed citations

20.

Thomé, Stephan D. & Dietlind L. Wahner‐Roedler. (1998). 71-Year-Old Woman With Palpitations and Dyspnea on Exertion. Mayo Clinic Proceedings. 73(11). 1109–1112. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact